Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Stromal fibronectin expression in patients with resected pancreatic ductal adenocarcinoma

Hu, Dingyuan LU ; Ansari, Daniel LU ; Zhou, Qimin LU orcid ; Sasor, Agata LU ; Said Hilmersson, Katarzyna LU and Andersson, Roland LU (2019) In World Journal of Surgical Oncology 17(1).
Abstract

Background: Pancreatic ductal adenocarcinoma (PDAC) is characterized by an extremely dense stroma, which has a fundamental role in tumor progression. Fibronectin (FN1) is the main constituent of the tumor stroma in pancreatic cancer. This study aimed to explore the association between FN1 and clinicopathological characteristics and disease survival. Methods: Formalin-fixed paraffin-embedded tissue samples from 138 patients with PDAC were constructed into a tissue microarray, followed by immunohistochemical analysis with a recombinant monoclonal FN1 antibody. Chi-square test or Fisher's exact test were used for comparison of FN1 expression and relevant clinicopathological parameters. Kaplan-Meier survival curves and Cox regression... (More)

Background: Pancreatic ductal adenocarcinoma (PDAC) is characterized by an extremely dense stroma, which has a fundamental role in tumor progression. Fibronectin (FN1) is the main constituent of the tumor stroma in pancreatic cancer. This study aimed to explore the association between FN1 and clinicopathological characteristics and disease survival. Methods: Formalin-fixed paraffin-embedded tissue samples from 138 patients with PDAC were constructed into a tissue microarray, followed by immunohistochemical analysis with a recombinant monoclonal FN1 antibody. Chi-square test or Fisher's exact test were used for comparison of FN1 expression and relevant clinicopathological parameters. Kaplan-Meier survival curves and Cox regression analyses were used to assess the association between FN1 and survival. Results: FN1 was detected in the stromal compartment in most cases (117/138, 84.8%). Compared to the low FN1 expression group, the high FN1 expression group had significantly larger tumor size (P = 0.002), more advanced T stage (P = 0.039) and N stage (P = 0.009), and also worse AJCC stage (P = 0.003). However, stromal FN1 expression was not associated with disease-free survival or overall survival. Conclusions: This study suggests that high stromal FN1 expression is associated with aggressive tumor characteristics in patients with resected PDAC. However, no association between FN1 expression and survival was found.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Fibronectin, Immunohistochemistry, Pancreatic ductal adenocarcinoma, Survival
in
World Journal of Surgical Oncology
volume
17
issue
1
article number
29
publisher
BioMed Central (BMC)
external identifiers
  • scopus:85061278622
  • pmid:30736807
ISSN
1477-7819
DOI
10.1186/s12957-019-1574-z
language
English
LU publication?
yes
id
786401dd-0807-488b-9376-751d87613251
date added to LUP
2019-02-19 07:40:29
date last changed
2024-12-11 00:53:22
@article{786401dd-0807-488b-9376-751d87613251,
  abstract     = {{<p>Background: Pancreatic ductal adenocarcinoma (PDAC) is characterized by an extremely dense stroma, which has a fundamental role in tumor progression. Fibronectin (FN1) is the main constituent of the tumor stroma in pancreatic cancer. This study aimed to explore the association between FN1 and clinicopathological characteristics and disease survival. Methods: Formalin-fixed paraffin-embedded tissue samples from 138 patients with PDAC were constructed into a tissue microarray, followed by immunohistochemical analysis with a recombinant monoclonal FN1 antibody. Chi-square test or Fisher's exact test were used for comparison of FN1 expression and relevant clinicopathological parameters. Kaplan-Meier survival curves and Cox regression analyses were used to assess the association between FN1 and survival. Results: FN1 was detected in the stromal compartment in most cases (117/138, 84.8%). Compared to the low FN1 expression group, the high FN1 expression group had significantly larger tumor size (P = 0.002), more advanced T stage (P = 0.039) and N stage (P = 0.009), and also worse AJCC stage (P = 0.003). However, stromal FN1 expression was not associated with disease-free survival or overall survival. Conclusions: This study suggests that high stromal FN1 expression is associated with aggressive tumor characteristics in patients with resected PDAC. However, no association between FN1 expression and survival was found.</p>}},
  author       = {{Hu, Dingyuan and Ansari, Daniel and Zhou, Qimin and Sasor, Agata and Said Hilmersson, Katarzyna and Andersson, Roland}},
  issn         = {{1477-7819}},
  keywords     = {{Fibronectin; Immunohistochemistry; Pancreatic ductal adenocarcinoma; Survival}},
  language     = {{eng}},
  month        = {{02}},
  number       = {{1}},
  publisher    = {{BioMed Central (BMC)}},
  series       = {{World Journal of Surgical Oncology}},
  title        = {{Stromal fibronectin expression in patients with resected pancreatic ductal adenocarcinoma}},
  url          = {{http://dx.doi.org/10.1186/s12957-019-1574-z}},
  doi          = {{10.1186/s12957-019-1574-z}},
  volume       = {{17}},
  year         = {{2019}},
}